RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
REPLIGEN CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $204.09M | $194.21M | $197.73M | $188.77M | $182.33M | $169.14M | $167.39M | $154.83M | $158.80M | $153.15M | $166.35M | $141.16M | 100.0% | +11.9% |
| Royalty and Other Revenue | $43.00K | $44.00K | $185.00K | $39.00K | $37.00K | $35.00K | $153.00K | $37.00K | $35.00K | $36.00K | $272.00K | $36.00K | 0.0% | +16.2% |
By region
From the segment and revenue-disaggregation notes of Repligen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.